{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:15:07Z","timestamp":1794071707142,"version":"4.8.0"},"reference-count":162,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008307","name":"Beckman Research Institute, City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["W81XWH-22-1-0331"],"award-info":[{"award-number":["W81XWH-22-1-0331"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["HT9425-25-1-0500"],"award-info":[{"award-number":["HT9425-25-1-0500"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.canlet.2026.218647","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:24:44Z","timestamp":1780356284000},"page":"218647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Inflammation-driven transcriptional reprogramming in prostate cancer: Convergence of NF\u03baB, JAK\/STAT3, and epigenetic remodeling in castration-resistant disease"],"prefix":"10.1016","volume":"655","author":[{"given":"Madhu","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-8160","authenticated-orcid":false,"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218647_bib1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218647_bib2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218647_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ceb.2015.10.002","article-title":"Cell types of origin for prostate cancer","volume":"37","author":"Lee","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218647_bib4","series-title":"StatPearls [Internet]","article-title":"Prostate cancer","author":"Leslie","year":"2026"},{"issue":"3","key":"10.1016\/j.canlet.2026.218647_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4111\/icu.20240456","article-title":"Evaluating prostate cancer diagnostic methods: the role and relevance of digital rectal examination in modern era","volume":"66","author":"Chung","year":"2025","journal-title":"Investig. Clin. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib6","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218647_bib7","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib8","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033688","article-title":"Metastases in prostate cancer","volume":"9","author":"Manna","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/1477-3163.83937","article-title":"Androgen receptor signaling in prostate cancer development and progression","volume":"10","author":"Lonergan","year":"2011","journal-title":"J. Carcinog."},{"key":"10.1016\/j.canlet.2026.218647_bib10","first-page":"232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218647_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","article-title":"Towards precision oncology in advanced prostate cancer","volume":"16","author":"Ku","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib12","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib13","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib17","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib19","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib20","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib21","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib22","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218647_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/pros.24110","article-title":"Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: a phase-2 nonrandomized clinical trial","volume":"81","author":"Shenderov","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218647_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2021.08.011","article-title":"Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial","volume":"81","author":"Kwan","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/1008-682X.122876","article-title":"PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance","volume":"16","author":"Edlind","year":"2014","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.canlet.2026.218647_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-55617-4_1","article-title":"Interleukin-6 function and targeting in prostate cancer","volume":"1290","author":"Culig","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2026.218647_bib31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.canlet.2026.218647_bib33","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0090-4295(01)01405-4","article-title":"Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis","volume":"58","author":"Shariat","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.canlet.2026.218647_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2026.218647_bib35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/pros.23015","article-title":"Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition","volume":"75","author":"Liu","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218647_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41420-020-0272-5","article-title":"Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells","volume":"6","author":"Cheteh","year":"2020","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.canlet.2026.218647_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cells7090122","article-title":"Inflammation and NF-kappaB signaling in prostate cancer: mechanisms and clinical implications","volume":"7","author":"Staal","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218647_bib38","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1017\/S1462399411001943","article-title":"Inflammation and wound healing: the role of the macrophage","volume":"13","author":"Koh","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12272-023-01428-3","article-title":"Distinctive role of inflammation in tissue repair and regeneration","volume":"46","author":"Choi","year":"2023","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.canlet.2026.218647_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrc2090","article-title":"Inflammation in prostate carcinogenesis","volume":"7","author":"De Marzo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","article-title":"Prostate cancer and inflammation: the evidence","volume":"60","author":"Sfanos","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2026.218647_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ph18091406","article-title":"Inflammation-driven genomic instability: a pathway to cancer development and therapy resistance","volume":"18","author":"Rembialkowska","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.canlet.2026.218647_bib43","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/S0002-9440(10)65517-4","article-title":"Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis","volume":"155","author":"De Marzo","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"Suppl 3","key":"10.1016\/j.canlet.2026.218647_bib44","first-page":"S11","article-title":"Prostatic intraepithelial neoplasia: an overview","volume":"7","author":"Brawer","year":"2005","journal-title":"Rev. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib45","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-kappaB in inflammation and cancer","volume":"22","author":"Mao","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218647_bib46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int. Immunol."},{"key":"10.1016\/j.canlet.2026.218647_bib47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-kappaB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib48","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/cam4.1186","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study","volume":"6","author":"Doat","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218647_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060786","article-title":"Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients","volume":"8","author":"Voiriot","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ijc.30061","article-title":"Risk of prostate cancer in low-dose aspirin users: a retrospective cohort study","volume":"139","author":"Lapi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib51","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41391-022-00554-1","article-title":"Statins and prostate cancer-hype or hope? The epidemiological perspective","volume":"25","author":"Craig","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canlet.2026.218647_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-025-02533-1","article-title":"Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications","volume":"25","author":"Huang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib53","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1073\/pnas.0437939100","article-title":"IL-1 is required for tumor invasiveness and angiogenesis","volume":"100","author":"Voronov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218647_bib54","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bju.12452","article-title":"Inflammation and prostate cancer: the role of interleukin 6 (IL6)","volume":"113","author":"Nguyen","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.canlet.2026.218647_bib55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2741\/1579","article-title":"The role of interleukin-8 in cancer cells and microenvironment interaction","volume":"10","author":"Yuan","year":"2005","journal-title":"Front. Biosci."},{"key":"10.1016\/j.canlet.2026.218647_bib56","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.3892\/mmr.2017.7747","article-title":"IL-8 promotes proliferation and inhibition of apoptosis via STAT3\/AKT\/NF-kappaB pathway in prostate cancer","volume":"16","author":"Guo","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2026.218647_bib57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","article-title":"Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells","volume":"12","author":"Gritsko","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib58","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.canlet.2026.218647_bib59","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218647_bib60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","article-title":"Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells","volume":"51","author":"Dutertre","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218647_bib61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41467-021-27322-4","article-title":"Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states","volume":"13","author":"Song","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218647_bib62","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/sj.bjc.6601705","article-title":"Role of infiltrated leucocytes in tumour growth and spread","volume":"90","author":"Lin","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071542","article-title":"Overcoming oncogenic mediated tumor immunity in prostate cancer","volume":"18","author":"Bryant","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218647_bib64","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218647_bib65","first-page":"485","article-title":"Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor","volume":"29","author":"Jing","year":"2011","journal-title":"Cancer Invest."},{"key":"10.1016\/j.canlet.2026.218647_bib66","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3389\/fonc.2019.01399","article-title":"Contribution of angiogenesis to inflammation and cancer","volume":"9","author":"Aguilar-Cazares","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0960-0760(97)00049-6","article-title":"Localization of functional domains in the androgen receptor","volume":"62","author":"MacLean","year":"1997","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2026.218647_bib68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen receptor (AR) coregulators: an overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.canlet.2026.218647_bib69","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000049782","article-title":"Molecular biology of the androgen receptor: from molecular understanding to the clinic","volume":"40","author":"Eder","year":"2001","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/aja202494","article-title":"Androgen receptor inhibitors in treating prostate cancer","volume":"27","author":"Cole","year":"2025","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.canlet.2026.218647_bib71","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1530\/EC-17-0118","article-title":"Clinical relevance of androgen receptor alterations in prostate cancer","volume":"6","author":"Jernberg","year":"2017","journal-title":"Endocr Connect."},{"key":"10.1016\/j.canlet.2026.218647_bib72","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251379416","article-title":"The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond","volume":"17","author":"Bernard-Tessier","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib73","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/aja.aja_19_19","article-title":"Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer","volume":"21","author":"Gritsina","year":"2019","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.canlet.2026.218647_bib75","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/nar\/gkw855","article-title":"Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-kappaB cistrome to reprogram the prostate cancer cell transcriptome","volume":"45","author":"Malinen","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2026.218647_bib76","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1128\/MCB.22.8.2862-2870.2002","article-title":"NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer","volume":"22","author":"Chen","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218647_bib77","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2353\/ajpath.2009.080727","article-title":"NF-kappaB regulates androgen receptor expression and prostate cancer growth","volume":"175","author":"Zhang","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218647_bib78","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/0008-5472.CAN-08-4423","article-title":"3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation","volume":"69","author":"Rahman","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib79","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/pros.20218","article-title":"Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells","volume":"64","author":"Lee","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218647_bib80","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pros.23140","article-title":"NF-kappaB and androgen receptor variant expression correlate with human BPH progression","volume":"76","author":"Austin","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218647_bib81","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1158\/0008-5472.CAN-08-0107","article-title":"The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth","volume":"68","author":"Jin","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib82","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218647_bib83","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/cancers6020897","article-title":"STAT3 target genes relevant to human cancers","volume":"6","author":"Carpenter","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218647_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1023177","article-title":"The role of IL6\/JAK2\/STAT3 signaling pathway in cancers","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib85","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/1947601910383417","article-title":"Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer","volume":"1","author":"Okitsu","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H","article-title":"Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer","volume":"41","author":"Drachenberg","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218647_bib87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.5306\/wjco.v2.i12.384","article-title":"IL6\/IL6R as a potential key signaling pathway in prostate cancer development","volume":"2","author":"Azevedo","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib88","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib89","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41391-025-00949-w","article-title":"Racial variation in the advanced prostate cancer genome","volume":"28","author":"Feng","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canlet.2026.218647_bib90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12253-011-9410-y","article-title":"Correlation analysis of JAK-STAT pathway components on prognosis of patients with prostate cancer","volume":"18","author":"Liu","year":"2012","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.canlet.2026.218647_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12020418","article-title":"Epithelial-Mesenchymal transition: a fundamental cellular and microenvironmental process in benign and malignant prostate pathologies","volume":"12","author":"Goncharov","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218647_bib92","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41388-023-02749-9","article-title":"Epigenetic regulation of hybrid epithelial-mesenchymal cell states in cancer","volume":"42","author":"Sample","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218647_bib93","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12967-025-06447-w","article-title":"Matrix metalloproteinase-driven epithelial-mesenchymal transition: implications in health and disease","volume":"23","author":"Khalili-Tanha","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib94","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3892\/or.2025.8942","article-title":"Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer","volume":"54","author":"Li","year":"2025","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2026.218647_bib95","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27871","article-title":"Androgen receptor, ccl2, and epithelial-mesenchymal transition: a dangerous affair in the tumor microenvironment","volume":"3","author":"Lin","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218647_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.650772","article-title":"The role of notch, hedgehog, and wnt signaling pathways in the resistance of tumors to anticancer therapies","volume":"9","author":"Kumar","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2026.218647_bib97","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","article-title":"Hallmarks of cancer stemness","volume":"31","author":"Loh","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2026.218647_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217737","article-title":"Cancer stem cells and tumor-associated macrophages: interactions and therapeutic opportunities","volume":"624","author":"Yuan","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218647_bib99","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218647_bib100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/path.2478","article-title":"Prostate cancer stem cells","volume":"217","author":"Lang","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218647_bib101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12672-010-0058-y","article-title":"Prostate cancer stem cells: do they have a basal or luminal phenotype?","volume":"2","author":"Maitland","year":"2011","journal-title":"Horm Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib102","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cell. Int."},{"key":"10.1016\/j.canlet.2026.218647_bib103","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1073\/pnas.79.1.61","article-title":"Clonal inheritance of the pattern of DNA methylation in mouse cells","volume":"79","author":"Stein","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218647_bib104","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.eururo.2004.07.022","article-title":"Molecular biomarker in prostate cancer: the role of CpG island hypermethylation","volume":"46","author":"Bastian","year":"2004","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib105","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2026.218647_bib106","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nature10008","article-title":"Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation","volume":"473","author":"Ficz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218647_bib107","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1158\/0008-5472.CAN-11-2023","article-title":"5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations","volume":"71","author":"Jin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib108","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/onc.2016.376","article-title":"TET2 binds the androgen receptor and loss is associated with prostate cancer","volume":"36","author":"Nickerson","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218647_bib109","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrg.2016.13","article-title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","volume":"17","author":"Feinberg","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2026.218647_bib110","first-page":"514","article-title":"Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features","volume":"8","author":"Maruyama","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib111","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ijc.11227","article-title":"Altered methylation of multiple genes in carcinogenesis of the prostate","volume":"106","author":"Yamanaka","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib112","first-page":"4730","article-title":"Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation","volume":"9","author":"Padar","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib113","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2026.218647_bib114","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/epi.3.6.7273","article-title":"The role of histone deacetylases in prostate cancer","volume":"3","author":"Abbas","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.canlet.2026.218647_bib115","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/cb400542w","article-title":"Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors","volume":"8","author":"Gryder","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.canlet.2026.218647_bib116","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1097-2765(02)00471-9","article-title":"Formation of the androgen receptor transcription complex","volume":"9","author":"Shang","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218647_bib117","first-page":"11623","article-title":"Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation","volume":"47","author":"Duan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2026.218647_bib118","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2026.218647_bib119","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13238-013-2093-2","article-title":"EZH2, an epigenetic driver of prostate cancer","volume":"4","author":"Yang","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.canlet.2026.218647_bib120","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting Bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mce.2017.03.012","article-title":"Interleukin-6 and prostate cancer: current developments and unsolved questions","volume":"462","author":"Culig","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2026.218647_bib122","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/pros.21362","article-title":"The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study","volume":"71","author":"Karkera","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218647_bib123","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1002\/cncr.24597","article-title":"Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218647_bib124","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1158\/1535-7163.MCT-18-0508","article-title":"The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models","volume":"17","author":"Handle","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218647_bib125","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3892\/ol.2014.1795","article-title":"Effects of AG490 and S3I-201 on regulation of the JAK\/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro","volume":"7","author":"Gurbuz","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2026.218647_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8050103","article-title":"Garcinol exhibits anti-neoplastic effects by targeting diverse oncogenic factors in tumor cells","volume":"8","author":"Aggarwal","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218647_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075414","article-title":"Sorafenib sensitizes solid tumors to Apo2L\/TRAIL and Apo2L\/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis","volume":"8","author":"Abdulghani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218647_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101495","article-title":"The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells","volume":"24","author":"Hellsten","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061451","article-title":"Targeting the JAK\/STAT signaling pathway using phytocompounds for cancer prevention and therapy","volume":"9","author":"Bose","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218647_bib130","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/JIR.S353489","article-title":"Role of JAK2\/STAT3 signaling pathway in the tumorigenesis, chemotherapy resistance, and treatment of solid tumors: a systemic review","volume":"15","author":"Mengie","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.canlet.2026.218647_bib131","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5489\/cuaj.5600","article-title":"Management algorithms for prostate-specific antigen progression in prostate cancer: biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer","volume":"13","author":"Danielson","year":"2019","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.canlet.2026.218647_bib132","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neo.2017.02.002","article-title":"Targeting NF-kappa B signaling by artesunate restores sensitivity of castrate-resistant prostate cancer cells to Antiandrogens","volume":"19","author":"Nunes","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218647_bib133","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-017-4261-1","article-title":"Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33\/2)","volume":"164","author":"von Hagens","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2026.218647_bib134","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1074\/jbc.M804491200","article-title":"Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression","volume":"284","author":"Willoughby","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2026.218647_bib135","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjp.0706176","article-title":"A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity","volume":"145","author":"Ziegelbauer","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218647_bib136","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1158\/1535-7163.MCT-15-0999","article-title":"Targeting IkappaB kinase beta\/NF-kappaB signaling in human prostate cancer by a novel IkappaB kinase beta inhibitor CmpdA","volume":"15","author":"Zhang","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218647_bib137","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1476-511X-13-56","article-title":"Effect of simvastatin on castration-resistant prostate cancer cells","volume":"13","author":"Kim","year":"2014","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.canlet.2026.218647_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184644","article-title":"Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB\/LIN28\/let-7 miRNA signaling pathway","volume":"12","author":"Kang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218647_bib139","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.juro.2012.10.030","article-title":"Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-kappaB pathway","volume":"189","author":"Park","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib140","doi-asserted-by":"crossref","first-page":"28973","DOI":"10.18632\/oncotarget.5023","article-title":"Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells","volume":"6","author":"Ge","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218647_bib141","first-page":"402","article-title":"A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer","volume":"2","author":"Heath","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.canlet.2026.218647_bib142","first-page":"166","article-title":"Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients","volume":"8","author":"Hwang","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"Suppl 2","key":"10.1016\/j.canlet.2026.218647_bib143","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000439307","article-title":"Role of BioResponse 3,3'-Diindolylmethane in the treatment of human prostate cancer: clinical experience","volume":"25","author":"Li","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.canlet.2026.218647_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2018.02.2264","article-title":"B cell concentration in high risk prostate cancer specimens after neoadjuvant rituximaB: MP70-20","volume":"199","author":"Ryan","year":"2018","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2026.218647_bib145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00163","article-title":"Past, present, and future of rituximab\u2014the world's first oncology monoclonal antibody therapy","volume":"8","author":"Pierpont","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib146","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kappaB signaling pathway in non-hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib147","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4161\/mabs.1.1.7472","article-title":"Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma","volume":"1","author":"Alinari","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.canlet.2026.218647_bib148","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1158\/1078-0432.CCR-17-1100","article-title":"Muscadine grape skin extract (MPX) in men with biochemically recurrent prostate cancer: a randomized, multicenter, placebo-controlled clinical trial","volume":"24","author":"Paller","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib149","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3945\/jn.113.186957","article-title":"Ocular inflammation and endoplasmic reticulum stress are attenuated by supplementation with grape polyphenols in human retinal pigmented epithelium cells and in C57BL\/6 mice","volume":"144","author":"Ha","year":"2014","journal-title":"J. Nutr."},{"key":"10.1016\/j.canlet.2026.218647_bib150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ctim.2018.05.002","article-title":"Association between dietary flavonoids intake and prostate cancer risk: a case-control study in Sicily","volume":"39","author":"Reale","year":"2018","journal-title":"Compl. Ther. Med."},{"key":"10.1016\/j.canlet.2026.218647_bib151","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/aje\/kws419","article-title":"Dietary flavonoid intake, black tea consumption, and risk of overall and advanced stage prostate cancer","volume":"177","author":"Geybels","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.canlet.2026.218647_bib152","first-page":"585","article-title":"Anti-androgenic effects of flavonols in prostate cancer","volume":"9","author":"Boam","year":"2015","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.canlet.2026.218647_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/nu13113750","article-title":"Kaempferol, myricetin and fisetin in prostate and bladder cancer: a systematic review of the literature","volume":"13","author":"Crocetto","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.canlet.2026.218647_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42682","article-title":"Phytochemical insights into flavonoids in cancer: mechanisms, therapeutic potential, and the case of quercetin","volume":"11","author":"Silva-Pinto","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.canlet.2026.218647_bib155","doi-asserted-by":"crossref","DOI":"10.1007\/s12257-019-0326-9","article-title":"Fisetin inhibits cell proliferation and induces apoptosis via JAK\/STAT3 signaling pathways in human thyroid TPC 1 cancer cells","volume":"25","author":"Liang","year":"2020","journal-title":"Biotechnol. Bioproc. Eng."},{"key":"10.1016\/j.canlet.2026.218647_bib156","first-page":"771","article-title":"The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells","volume":"39","author":"Szliszka","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2026.218647_bib157","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1007\/s11033-022-07307-2","article-title":"Kaempferol suppresses androgen-dependent and androgen-independent prostate cancer by regulating Ki67 expression","volume":"49","author":"Zhang","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2026.218647_bib158","first-page":"54","article-title":"STAT3 and NF-kappaB are common targets for kaempferol-mediated attenuation of COX-2 expression in IL6-induced macrophages and carrageenan-induced mouse paw edema","volume":"12","author":"Basu","year":"2017","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.canlet.2026.218647_bib159","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11033-024-09567-6","article-title":"Recent advances in flavonoid compounds for the treatment of prostate cancer","volume":"51","author":"Fang","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.canlet.2026.218647_bib160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3892\/or.2014.3218","article-title":"2'-hydroxyflavanone inhibits prostate tumor growth through inactivation of AKT\/STAT3 signaling and induction of cell apoptosis","volume":"32","author":"Wu","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2026.218647_bib161","first-page":"4453","article-title":"Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone","volume":"33","author":"Ofude","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2026.218647_bib162","article-title":"The effect and mechanism of 2\u2019-hydroxyflavanone\u2019s impact on the radiosensitization of prostate cancer cells","volume":"96","author":"Wang","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:38:18Z","timestamp":1782488298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":162,"alternative-id":["S0304383526004106"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218647","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation-driven transcriptional reprogramming in prostate cancer: Convergence of NF\u03baB, JAK\/STAT3, and epigenetic remodeling in castration-resistant disease","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218647"}}